While Using This Medicine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from While using this medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In While Using This Medicine Today - Breaking & Trending Today

Hikma launches generic Advair Diskus® following FDA approval

Hikma launches generic Advair Diskus® following FDA approval
News provided by
Share this article
Share this article
LONDON, Dec. 17, 2020 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline s Advair Diskus
®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.
Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology.
According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020. ....

United Arab Emirates , United States , United Kingdom , City Of , Steve Weiss , Charles Armitstead Camilla Cunningham , Glaxosmithkline Advair Diskus , Susan Ringdal , Siggi Olafsson , David Belian , Advair Diskus , Vectura Group , Global Affairs , Ward Columbus Inc , Hikma Pharmaceuticals United States Inc , Us Communications , Public Affairs , Hikma Pharmaceuticals , Fluticasone Propionate , Salmeterol Inhalation Powder , Chief Executive Officer , Strategic Planning , Camilla Cunningham , Middle East , North Africa , Safety Information ,

Investegate |Hikma Pharmaceutical Announcements | Hikma Pharmaceutical: Hikma launches generic Advair Diskus

London, 17
December 2020

-
Hikma Pharmaceuticals PLC
(Hikma), the multinational pharmaceutical company, annou
nces it has received FDA approval for and launched its generic version of GlaxoSmithKline s Advair Diskus
®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology.

According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020.

Siggi Olafsson, Chief Executive Officer of Hikma, said The approval of our generic version of Advair Diskus ....

United Arab Emirates , United States , United Kingdom , City Of , Steve Weiss , Charles Armitstead Camilla Cunningham , Glaxosmithkline Advair Diskus , Susan Ringdal , Siggi Olafsson , David Belian , Advair Diskus , Vectura Group , Global Affairs , Ward Columbus Inc , Hikma Pharmaceuticals United States Inc , Us Communications , Public Affairs , Hikma Pharmaceuticals , Fluticasone Propionate , Salmeterol Inhalation Powder , Chief Executive Officer , Strategic Planning , Camilla Cunningham , Middle East , North Africa , Safety Information ,